Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection

Detalhes bibliográficos
Autor(a) principal: Duarte,Rita Carolina Figueiredo
Data de Publicação: 2021
Outros Autores: Moreira,Priscila Samara Sérgio, Ferreira,Cláudia Natália, Figueiredo,Estevão Lanna, Sternick,Eduardo, Silveira,Francisco Rezende, Alves,Luan Carlos Vieira, Mota,Ana Paula Lucas, Reis,Edna Afonso, Carvalho,Maria das Graças, Reis,Helton José dos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Journal of Cardiovascular Sciences (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472021000200116
Resumo: Abstract Background Traditionally, the most effective therapy in the prevention of stroke in patients with atrial fibrillation (AF) has been oral anticoagulation with vitamin K inhibitors, particularly warfarin, whose disadvantages and adverse effects have led to their replacement by "direct oral anticoagulants", as factor X inhibitor. Objectives This study aimed to conduct a brief approach on atrial fibrillation (AF) and use of Rivaroxaban, and to comparatively evaluate the prothrombin time / International Normalized Ratio (PT/INR) in patients with AF in use of this oral anticoagulant, depending on the time elapsed between the last administration of the drug and the time of blood sample venipuncture. Methods We evaluated 34 patients with AF in use of Rivaroxaban by using PT / INR, distributed into a subgroup with blood collection time ≤ 12 hours (n = 7) and > 12 hours after the last drug intake (n = 27). Mann-Whitney test was used to compare the groups and p < 0.05 was considered significant. Results An analysis as a function of time between the Rivaroxaban intake and blood collection, revealed that PT / INR suffers the greatest effect up to 12 hours after ingestion of the drug, dropping to levels close to normal in subsequent hours before the next dose. Conclusion We concluded that, in contrast to warfarin, the knowledge of the time interval between drug intake and blood collection from patients taking Rivaroxaban is essential to properly interpret a laboratory test to assess hemostasis, particularly PT and its derivatives. Int J Cardiovasc Sci. 2020; [online].ahead print, PP.0-0
id SBC-2_c46832dbcc5fd775d002396fc069e4c5
oai_identifier_str oai:scielo:S2359-56472021000200116
network_acronym_str SBC-2
network_name_str International Journal of Cardiovascular Sciences (Online)
repository_id_str
spelling Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood CollectionAtrial FibrillationStrokeEmbolismRivaroxabanWarfarinAnticoagulantsHemorrhage/physiopathologyRisk AssessmentBlood CoagulationAbstract Background Traditionally, the most effective therapy in the prevention of stroke in patients with atrial fibrillation (AF) has been oral anticoagulation with vitamin K inhibitors, particularly warfarin, whose disadvantages and adverse effects have led to their replacement by "direct oral anticoagulants", as factor X inhibitor. Objectives This study aimed to conduct a brief approach on atrial fibrillation (AF) and use of Rivaroxaban, and to comparatively evaluate the prothrombin time / International Normalized Ratio (PT/INR) in patients with AF in use of this oral anticoagulant, depending on the time elapsed between the last administration of the drug and the time of blood sample venipuncture. Methods We evaluated 34 patients with AF in use of Rivaroxaban by using PT / INR, distributed into a subgroup with blood collection time ≤ 12 hours (n = 7) and > 12 hours after the last drug intake (n = 27). Mann-Whitney test was used to compare the groups and p < 0.05 was considered significant. Results An analysis as a function of time between the Rivaroxaban intake and blood collection, revealed that PT / INR suffers the greatest effect up to 12 hours after ingestion of the drug, dropping to levels close to normal in subsequent hours before the next dose. Conclusion We concluded that, in contrast to warfarin, the knowledge of the time interval between drug intake and blood collection from patients taking Rivaroxaban is essential to properly interpret a laboratory test to assess hemostasis, particularly PT and its derivatives. Int J Cardiovasc Sci. 2020; [online].ahead print, PP.0-0Sociedade Brasileira de Cardiologia2021-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472021000200116International Journal of Cardiovascular Sciences v.34 n.2 2021reponame:International Journal of Cardiovascular Sciences (Online)instname:Sociedade Brasileira de Cardiologia (SBC)instacron:SBC10.36660/ijcs.20190141info:eu-repo/semantics/openAccessDuarte,Rita Carolina FigueiredoMoreira,Priscila Samara SérgioFerreira,Cláudia NatáliaFigueiredo,Estevão LannaSternick,EduardoSilveira,Francisco RezendeAlves,Luan Carlos VieiraMota,Ana Paula LucasReis,Edna AfonsoCarvalho,Maria das GraçasReis,Helton José doseng2022-02-02T00:00:00Zoai:scielo:S2359-56472021000200116Revistahttp://publicacoes.cardiol.br/portal/ijcshttps://old.scielo.br/oai/scielo-oai.phptailanerodrigues@cardiol.br||revistaijcs@cardiol.br2359-56472359-4802opendoar:2022-02-02T00:00International Journal of Cardiovascular Sciences (Online) - Sociedade Brasileira de Cardiologia (SBC)false
dc.title.none.fl_str_mv Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection
title Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection
spellingShingle Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection
Duarte,Rita Carolina Figueiredo
Atrial Fibrillation
Stroke
Embolism
Rivaroxaban
Warfarin
Anticoagulants
Hemorrhage/physiopathology
Risk Assessment
Blood Coagulation
title_short Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection
title_full Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection
title_fullStr Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection
title_full_unstemmed Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection
title_sort Atrial Fibrillation and Use of Rivaroxaban: Performance of the Prothrombin Time / INR as a Function of Time After Blood Collection
author Duarte,Rita Carolina Figueiredo
author_facet Duarte,Rita Carolina Figueiredo
Moreira,Priscila Samara Sérgio
Ferreira,Cláudia Natália
Figueiredo,Estevão Lanna
Sternick,Eduardo
Silveira,Francisco Rezende
Alves,Luan Carlos Vieira
Mota,Ana Paula Lucas
Reis,Edna Afonso
Carvalho,Maria das Graças
Reis,Helton José dos
author_role author
author2 Moreira,Priscila Samara Sérgio
Ferreira,Cláudia Natália
Figueiredo,Estevão Lanna
Sternick,Eduardo
Silveira,Francisco Rezende
Alves,Luan Carlos Vieira
Mota,Ana Paula Lucas
Reis,Edna Afonso
Carvalho,Maria das Graças
Reis,Helton José dos
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Duarte,Rita Carolina Figueiredo
Moreira,Priscila Samara Sérgio
Ferreira,Cláudia Natália
Figueiredo,Estevão Lanna
Sternick,Eduardo
Silveira,Francisco Rezende
Alves,Luan Carlos Vieira
Mota,Ana Paula Lucas
Reis,Edna Afonso
Carvalho,Maria das Graças
Reis,Helton José dos
dc.subject.por.fl_str_mv Atrial Fibrillation
Stroke
Embolism
Rivaroxaban
Warfarin
Anticoagulants
Hemorrhage/physiopathology
Risk Assessment
Blood Coagulation
topic Atrial Fibrillation
Stroke
Embolism
Rivaroxaban
Warfarin
Anticoagulants
Hemorrhage/physiopathology
Risk Assessment
Blood Coagulation
description Abstract Background Traditionally, the most effective therapy in the prevention of stroke in patients with atrial fibrillation (AF) has been oral anticoagulation with vitamin K inhibitors, particularly warfarin, whose disadvantages and adverse effects have led to their replacement by "direct oral anticoagulants", as factor X inhibitor. Objectives This study aimed to conduct a brief approach on atrial fibrillation (AF) and use of Rivaroxaban, and to comparatively evaluate the prothrombin time / International Normalized Ratio (PT/INR) in patients with AF in use of this oral anticoagulant, depending on the time elapsed between the last administration of the drug and the time of blood sample venipuncture. Methods We evaluated 34 patients with AF in use of Rivaroxaban by using PT / INR, distributed into a subgroup with blood collection time ≤ 12 hours (n = 7) and > 12 hours after the last drug intake (n = 27). Mann-Whitney test was used to compare the groups and p < 0.05 was considered significant. Results An analysis as a function of time between the Rivaroxaban intake and blood collection, revealed that PT / INR suffers the greatest effect up to 12 hours after ingestion of the drug, dropping to levels close to normal in subsequent hours before the next dose. Conclusion We concluded that, in contrast to warfarin, the knowledge of the time interval between drug intake and blood collection from patients taking Rivaroxaban is essential to properly interpret a laboratory test to assess hemostasis, particularly PT and its derivatives. Int J Cardiovasc Sci. 2020; [online].ahead print, PP.0-0
publishDate 2021
dc.date.none.fl_str_mv 2021-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472021000200116
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-56472021000200116
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.36660/ijcs.20190141
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Cardiologia
publisher.none.fl_str_mv Sociedade Brasileira de Cardiologia
dc.source.none.fl_str_mv International Journal of Cardiovascular Sciences v.34 n.2 2021
reponame:International Journal of Cardiovascular Sciences (Online)
instname:Sociedade Brasileira de Cardiologia (SBC)
instacron:SBC
instname_str Sociedade Brasileira de Cardiologia (SBC)
instacron_str SBC
institution SBC
reponame_str International Journal of Cardiovascular Sciences (Online)
collection International Journal of Cardiovascular Sciences (Online)
repository.name.fl_str_mv International Journal of Cardiovascular Sciences (Online) - Sociedade Brasileira de Cardiologia (SBC)
repository.mail.fl_str_mv tailanerodrigues@cardiol.br||revistaijcs@cardiol.br
_version_ 1754732626643517440